Antidepressant Drug Prescription and Risk of Abnormal Bleeding
Authors:
- Margherita AndrettaMAMargherita Andretta
- Giuseppe De VitisGVGiuseppe De Vitis
- Elisa RossiERElisa Rossi
- Fabrizio D'ARienzoFDFabrizio D'ARienzo
- Luigi MezzaliraLMLuigi Mezzalira
- Marisa De RosaMRMarisa De Rosa
- Andrea CiprianiACAndrea Cipriani
- Alessandra BertiABAlessandra Berti
- Michela NosèMNMichela Nosè
- Michele TansellaMTMichele Tansella
- Luigi BozziniLBLuigi Bozzini
- 1 February 2009
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 29 (1) , 33-38
Abstract
This study assessed the risk of any bleeding abnormalities, including the risk of gastrointestinal bleeding, associated with antidepressant exposure. We used a case-control methodology. Case patients were individuals admitted with a diagnosis of abnormal bleeding. Control subjects were individuals admitted on the same date without evidence of abnormal bleeding. During the study period, 11,025 case patients were admitted for bleeding abnormalities (matched with 21,846 eligible control subjects), and 1008 were admitted for gastrointestinal bleeding (matched with 1990 eligible control subjects). With respect to any bleeding abnormalities, antidepressants as a group were not associated with an increased risk (adjusted odds ratio [OR], 0.99; 95% confidence interval [CI], 0.90-1.08). Similarly, selective serotonin reuptake inhibitors as a group, the group of tricyclic and related antidepressants, and the group of other antidepressants were not associated with an increased risk of bleeding. With respect to gastrointestinal bleeding abnormalities, antidepressants as a group were associated with a modestly increased risk (adjusted OR, 1.34; 95% CI, 1.01-1.80). Whereas the group of tricyclic and related antidepressants was not associated with an increased risk of bleeding, the group of selective serotonin reuptake inhibitors was associated with a nonsignificant trend toward an increased risk of bleeding (adjusted OR, 1.31; 95% CI, 0.91-1.88) and the group of other antidepressants with a statistically significant increase in the risk of bleeding (adjusted OR, 1.74; 95% CI, 1.04-2.93). In a population with a low baseline risk of bleeding, we detected a significant increase in the risk of gastrointestinal bleeding only.Keywords
This publication has 17 references indexed in Scilit:
- Risk of Upper Gastrointestinal Bleeding and the Degree of Serotonin Reuptake Inhibition by AntidepressantsDrug Safety, 2008
- Metareview on Short-Term Effectiveness and Safety of Antidepressants for Depression: An Evidence-Based Approach to Inform Clinical PracticeThe Canadian Journal of Psychiatry, 2007
- The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic reviewJournal of Intellectual Disability Research, 2007
- Issues in the pharmacological treatment of obsessive-compulsive disorderInternational Journal Of Clinical Practice, 2007
- Diagnosis and Treatment of Agoraphobia with Panic DisorderCNS Drugs, 2007
- Selective Serotonin Reuptake Inhibitors and Risk of Upper GI Bleeding: Confusion or Confounding?The American Journal of Medicine, 2006
- Antidepressants and Risk of Upper Gastrointestinal BleedingBasic & Clinical Pharmacology & Toxicology, 2006
- Selective Serotonin Reuptake Inhibitors and Increased Bleeding Risk: Are We Missing Something?The American Journal of Medicine, 2006
- SSRIs and Upper Gastrointestinal BleedingCNS Drugs, 2006
- Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by AntidepressantsArchives of internal medicine (1960), 2004